Christian Singer, MD, Medical University of Vienna, Vienna, Austria discusses the role of CDK4/6 inhibitors in combination with endocrine therapy (ET) for hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer. He confirms this combination as a well-established first-line option in the advanced setting, using either aromatase inhibitors or fulvestrant. As these agents move into earlier disease stages for high- and intermediate-risk patients, their role upon progression may be influenced by the disease-free interval. In rapidly progressing cases, alternative or more complex treatment strategies, including possible reintroduction of CDK4/6 inhibitors, may be considered. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
